FF-10101 is an irreversible, type I covalent inhibitor of FLT3 that has exhibited activity against R/R AML, including those with activating FLT3-ITD mutations resistant to gilteritinib, quizartinib, and other FLT3 kinase inhibitors. This evidence concerns the gene FLT3 and acute myeloid leukemia.